{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:23:05Z","timestamp":1772202185267,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Programma Nazionale AIDS project number 40H94"},{"name":"Janssen Europe provided Darunavir tablets for patients in the study arm and supported the pharmacovigilance of the study"},{"name":"ViiV Healthcare Italy supported tropism testing for all patients"},{"name":"ViiV Healthcare Italy supported plasma antiretroviral drug monitoring for patients in the study arm"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0187393","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T13:26:11Z","timestamp":1511270771000},"page":"e0187393","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Switch to maraviroc with darunavir\/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-9241","authenticated-orcid":true,"given":"Barbara","family":"Rossetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genny","family":"Meini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Colangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carla","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Latini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Colafigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vignale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Ghisetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fantauzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Vullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Grima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Trezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Canovari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"D\u2019Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Lamonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"D\u2019Avino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for GUSTA trial study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/cir526","article-title":"Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy","volume":"53","author":"MJ Mugavero","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; January 28, 2016. (17 Jun 2017, date last accessed)."},{"key":"ref3","unstructured":"European AIDS Clinical Society (EACS). Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe, Prevention and Management of Non-Infectious Comorbidities in HIV, Version 8.2, January 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.europeanaidsclinicalsociety.org\/images\/stories\/EACS-Pdf\/EACSGuidelines-v8.2-English-Jan2017.pdf\" xlink:type=\"simple\">http:\/\/www.europeanaidsclinicalsociety.org\/images\/stories\/EACS-Pdf\/EACSGuidelines-v8.2-English-Jan2017.pdf<\/ext-link> (17 Jun 2017, date last accessed)."},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016. Recommendations of the International Antiviral Society-USA Panel","volume":"316","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"PM Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1179\/1528433614Z.0000000001","article-title":"Renal safety of coformulated tenofovir\/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study","volume":"16","author":"E Pedrol","year":"2015","journal-title":"HIV Clin Trials"},{"issue":"4 Suppl 3","key":"ref7","doi-asserted-by":"crossref","first-page":"19824","DOI":"10.7448\/IAS.17.4.19824","article-title":"Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor","volume":"17","author":"M Fisher","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12916-016-0588-4","article-title":"Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration","volume":"14","author":"CA Sabin","year":"2016","journal-title":"BMC Med"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"JA Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkr504","article-title":"Long-term efficacy of darunavir\/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study","volume":"67","author":"MA Valantin","year":"2012","journal-title":"J Antimicrob Chemoter"},{"key":"ref11","article-title":"Treatment simplification to atazanavir\/ritonavir + lamivudine versus maintenance of atazanavir\/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)","author":"S Di Giambenedetto","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref12","article-title":"Dual raltegravir-etravirine combination as maintenance regimen in virologically suppressed HIV-1-infected patients","author":"L Calza","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2","volume":"55","author":"WD Hardy","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0000000000000131","article-title":"Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings","volume":"28","author":"DA Cooper","year":"2014","journal-title":"AIDS"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/QAD.0000000000001058","article-title":"Once-daily maraviroc versus tenofovir\/emtricitabine each combined with darunavir\/ritonavir for initial HIV-1 treatment","volume":"30","author":"HJ Stellbrink","year":"2016","journal-title":"AIDS"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","article-title":"Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study","volume":"62","author":"A Mills","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"ref17","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1479-5876-9-S1-S6","article-title":"Selective transmission of R5 HIV-1 variants: where is the gatekeeper?","volume":"9","author":"JC Grivel","year":"2011","journal-title":"J Transl Med"},{"key":"ref18","article-title":"Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside\/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study","author":"SL Pett","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","article-title":"European guidelines on the clinical management of HIV-1 tropism testing","volume":"11","author":"LP Vandekerckhove","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1742-4690-7-56","article-title":"Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop","volume":"7","author":"MC Prosperi","year":"2010","journal-title":"RNA and DNA genotyping. Retrovirology"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/cir493","article-title":"Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc","volume":"53","author":"LC Swenson","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/dkt426","article-title":"Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy","volume":"69","author":"G Meini","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s15010-013-0510-3","article-title":"Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group","volume":"42","author":"V Svicher","year":"2014","journal-title":"Infection"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/QAI.0b013e3181ed1932","article-title":"Asymmetry of the regimenis correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy","volume":"55","author":"R Murri","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","article-title":"Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection","volume":"28","author":"A Ammassari","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jac\/dkr493","article-title":"Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800\/100 mg","volume":"67","author":"C Okoli","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"e105853","DOI":"10.1371\/journal.pone.0105853","article-title":"A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-na\u00efve patients starting a first-line HAART","volume":"9","author":"D Armenia","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"JR Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/cid\/civ455","article-title":"Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study","volume":"61","author":"BO Taiwo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir pluslamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non inferiority trial","volume":"15","author":"JR Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"JA Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref32","unstructured":"Gagliardini R, Fabbiani M, Quiros Roldan E, Latini A, D\u2019Ettore G, Antinori A et al. Simplification to atazanavir\/ritonavir lamivudine versus maintaining atazanavir\/ritonavir 2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial. O121, International Congress on HIV Drug Therapy; 2016 Oct 23\u201326; Glasgow, UK."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jinf.2016.08.011","article-title":"Simplification to a dual regimen with darunavir\/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV infected patients","volume":"73","author":"M Fabbiani","year":"2016","journal-title":"J Infect"},{"key":"ref34","unstructured":"Pulido F, Ribera E, Lagarde M, Perez-Valero I, Santos J, Iribarren JA, et al. Non-inferiority of dual therapy (DT) with darunavir\/ritonavir (DRV\/r) plus 3TC versus triple-therapy (TT) with DRV\/r plus TDF\/FTC or ABC\/ 3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial. O331, International Congress on HIV Drug Therapy; 2016 Oct 23\u201326, Glasgow, UK."},{"key":"ref35","unstructured":"Llibre JM, Hung C-C BC, Castelli F, Girard PM, Kahl Let al. Phase III SWORD 1 &amp; 2: Switch to DTG + RPV maintains virologic suppression thorugh 48 wks. O-4 Abstract 44LB, 24th Conference on Retroviruses and Opportunistic Infections (CROI); 2017; Febr 13\u201316; Seattle, US."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0187393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:35:32Z","timestamp":1588970132000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0187393"}},"subtitle":[],"editor":[{"given":"D William","family":"Cameron","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0187393","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.17504\/protocols.io.jmnck5e","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}